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Background: Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed.
Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant
systemic therapy (n = 766).
Methods: AURKA was analyzed using microarray-based gene-expression data from three independent cohorts of
node-negative breast cancer patients. In multivariate Cox analyses, the prognostic impact of age, histological grade,
tumor size, estrogen receptor (ER), and HER2 were considered.
Results: Patients with higher AURKA expression had a shorter metastasis-free survival (MFS) in the Mainz (HR 1.93;
95% CI 1.34 – 2.78; P < 0.001), Rotterdam (HR 1.95; 95% CI 1.45– 2.63; P<0.001) and Transbig (HR 1.52; 95% CI
1.14–2.04; P=0.005) cohorts. AURKA was also associated with MFS in the molecular subtype ER+/HER2- carcinomas
(HR 2.10; 95% CI 1.70–2.59; P<0.001), but not in ER-/HER2- nor in HER2+ carcinomas. In the multivariate Cox
regression adjusted to age, grade and tumor size, AURKA showed independent prognostic significance in the ER
+/HER2- subtype (HR 1.73; 95% CI 1.24–2.42; P=0.001). Prognosis of patients in the highest quartile of AURKA
expression was particularly poor. In addition, AURKA correlated with the proliferation metagene (R=0.880; P<0.001),
showed a positive association with grade (P<0.001), tumor size (P<0.001) and HER2 (P<0.001), and was inversely
associated with ER status (P<0.001).
Conclusions: AURKA is associated with worse prognosis in estrogen receptor positive breast carcinomas. Patients
with the highest AURKA expression (>75% percentile) have a particularly bad prognosis and may profit from
therapy with AURKA inhibitors.
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Aurora kinases A and B are both important for cell cycle
progression. They are frequently overexpressed or
mutated in human tumor proteins [1,2], and have been
implicated in tumor formation and progression [3,4].
Both kinases are highly expressed in several tumor types,
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distribution, and reproduction in any mediumskin, stomach, rectum, esophagus, endometrium, cervix,
bladder, ovary, and thyroid cancers compared to the cor-
responding normal tissues [1,2]. Aurora kinase A
(AURKA) is also involved in centrosome function and
assembly of the mitotic spindle [5], and has been shown
to modulate the activity of tumor suppressors such as
p53 [1].
Inhibition of aurora kinase in xenograft models results
in tumor regression [6]. Furthermore, inhibitors that tar-
get this family of kinases are currently under clinical de-
velopment. These agents selectively target the enzymatictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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enosine triphosphate (ATP)-binding site [7-9].
Several studies have assessed the importance of aurora
kinase A and B in breast cancer. In a mouse model,
AURKA overexpression was shown to induce breast
tumor formation in mammary epithelium [10]. More-
over, polymorphisms in the AURKA gene are associated
with increased risk of primary breast cancer [10,11]. This
association is synergistic in its effect on the risk of breast
cancer in women with prolonged estrogen exposure
[12]. AURKA regulates the transition of cells from the
G2 to M phase and has been shown to be responsible
for the phosphorylation of BRCA1 [13]. Other studies
have assessed the expression of AURKA in human breast
cancer tissue. For example, Tanaka et al. [14] investi-
gated 33 cases of invasive ductal carcinoma and found
AURKA overexpressed in 94% of cases. Miyoshi et al.
observed elevated expression in 64% of breast carcin-
omas using reverse transcription polymerase chain reac-
tion (PCR) in 47 patients [15]. However, a larger study
including 112 patients did not find an association be-
tween AURKA expression and survival [16]. Further-
more, Nadler et al. observed variable expression of
aurora kinase A and B in primary breast tumors [17]. In
their study, high levels of AURKA was strongly asso-
ciated with decreased survival (P = 0.0005) and contin-
ued to be an independent prognostic marker in the
multivariate analysis. High AURKA expression was also
associated with high nuclear grade, high HER-2 and pro-
gesterone receptor expression. Aurora kinase B expres-
sion was not associated with survival [17].
Gene expression profiling has led to a magnitude of
different signatures which are related to breast cancer
prognosis. In a meta-analysis of publicly available breast
cancer gene expression and clinical data, Wiripati and
co-workers underscored the important role of prolifera-
tion in breast cancer prognosis [18]. Clearly, there are
numerous proliferation-associated genes. Martin and co-
workers used a novel unsupervised approach to identify
a set of genes whose expression predicts prognosis of
breast cancer patients [19]. Amongst the most pre-
dictive genes for ER positive patients was AURKA, a
gene which is a constituent in multiple microarray gene
signatures [20-22].
Meanwhile, in a head to head comparison of a large
panel of proliferation markers using immunohistochem-
istry in 3.093 breast carcinomas AURKA outperformed
other proliferation markers as an independent predictor
of breast cancer-specific survival in ER-positive breast
cancer [23]. Finally, a sophisticated analysis of prognosti-
cation strategies in breast cancer microarray data sets
showed that that the most complex methods were not
necessarily better than a univariate model relying on a
single gene like AURKA [24]. We could also show thatexpression of AURKA was associated with survival in
node-negative breast cancer in univariate but not in
multivariate analysis [25].
In view of the importance of AURKA in malignant
progression, together with the current development of
aurora kinase inhibitors, we set out to analyze the
prognostic significance of AURKA in cohorts of node-




This analysis includes gene array data from node-
negative breast cancer patients without adjuvant chemo-
therapy. The study was approved by the ethical review
board of the medical association of Rhineland-Palatinate.
The manuscript was prepared in agreement with the
reporting recommendations for tumor marker reporting
studies [26].
Gene array data for fresh frozen tissue
Three previously published datasets for untreated node-
negative breast cancer patients were used. The large
combined group of 766 patients included the Mainz co-
hort with 200 patients (Table 1) [27], the Rotterdam co-
hort with 286 patients (Table 2) [28], and the
TRANSBIG cohort with 280 patients (Table 3) [29,30].
These cohorts comprise available microarray datasets for
medically untreated node-negative breast cancer which
have used metastasis-free survival (MFS) as an end
point.
Gene expression profiling and data processing
For the Mainz, Rotterdam, and TRANSBIG cohorts, the
Affymetrix, Inc. (Santa Clara, California) Human Gen-
ome U133A Array set and GeneChip SystemTM were
used to quantify the relative transcript abundance in the
breast cancer tissues, as previously described [27], and
the robust multiarray average (RMA) algorithm was
used for normalization. To analyze AURKA expression
from the gene array data, probe set ID 204092_s_at was
used in all cohorts.
Statistical analysis
Survival rates were calculated using the Kaplan–Meier
method. Metastasis-free survival was computed from the
date of diagnosis to the date of distant metastasis. Sur-
vival functions were compared with the Log-rank test.
Multivariate Cox survival analyses were performed with
inclusion. Categorization was performed as follows: aur-
ora kinase mRNA: < median, ≥ median; age: < 50 years,
≥ 50 years; HER-2 status, ER status, PR status: negative,
positive; histological grade: GI and GII, GIII; pT stage:
pT1 (≤ 2 cm), pT2 and pT3 (> 2 cm). Hormone receptor
Table 1 Clinicopathological characteristics of node
negative breast cancer patients (fresh frozen tissue) from








not documented 6 3.0
Histological grade
G I 42 21.0
G II 109 54.5
G III 49 24.5
Estrogen receptor status1
RNA expression low 31 15.5
RNA expression high 169 84.5
Progesterone receptor status1
RNA expression low




RNA expression high 31 15.5
169 84.5
HER2 status1
RNA expression low 181 90.5




1Estrogen, progesterone and HER2 status were derived from RNA levels as
described in Schmidt et al., 2010 [34]. 2The hormone receptor status is defined
as positive when one of either the estrogen or the progesterone receptor
status is positive.
Table 2 Clinicopathological characteristics of node
negative breast cancer patients (fresh frozen tissue) from
the Rotterdam cohort (n=286)
Characteristics n %
Estrogen receptor
RNA expression low 78 27.3
RNA expression high 208 72.7
Progesterone receptor
RNA expression low 158 55.2
RNA expression high 128 44.8
Hormone receptor status1
RNA expression low
RNA expression high 76 26.6
210 73.4
HER2 status
RNA expression low 236 82.5




Estrogen receptor, progesterone receptor and HER-2 status were derived from
the gene array data. Cut-points were 8.2 for the estrogen receptor, 11.2 for
HER-2, and 4.5 for the progesterone receptor. Log2 transformed gene array
data have been used.
1The hormone receptor status is positive when either the estrogen or
progesterone receptor RNA expression is high.
Siggelkow et al. BMC Cancer 2012, 12:562 Page 3 of 11
http://www.biomedcentral.com/1471-2407/12/562status was dichotomized on the basis of the correspond-
ing gene expression values. All p-values are two-sided.
As no correction for multiple testing was performed
they are descriptive measures. All analyses were per-
formed using R2.12.1.
Results
To study the prognostic impact of AURKA, we used
three publicly accessible Affymetrix gene array data sets,
more specifically only node-negative breast cancer
patients who did not receive chemotherapy: the Mainz,
Rotterdam, and Transbig cohorts (Tables 1, 2, and 3)
[27-30]. Expression of AURKA was detectable in all car-
cinomas and showed a unimodal distribution. AURKA
was associated with metastasis-free interval (MFI) in thecombined cohort as well as in all three subcohorts using
the univariate Cox analysis (Table 4). Similarly, Kaplan-
Meier analysis showed a strong association between high
AURKA expression and shorter MFI (Figure 1). Next,
we studied whether patients with the highest expression
levels of AURKA suffer from a particularly high risk of
metastasis. For this purpose, we subdivided the 766
patients into four (Figure 2A) and six (Figure 2B) equal
groups with increasing levels of AURKA. This analysis
illustrates that patients with AURKA levels between the
25 and 50% percentile suffer from shorter metastasis-
free survival than patients with expression below the
25% percentile. The 25% of carcinomas with the highest
expression (>75% percentile) have the worse prognosis
(Figure 2A). Additional subdivision into six groups of
equal size did not allow a further differentiation
(Figure 2B).
Breast cancer is not a homogeneous disease, making it
necessary to differentiate among the different molecular
subtypes. A frequently applied system was introduced
by Desmedt et al., differentiating between ER+/HER2-,
ER-/HER2- and HER2+ carcinomas [31]. Interestingly,
only the ER+/HER2- molecular subtype showed an asso-
ciation between AURKA and MFI, a result relevant
for the total cohort (Table 4), as well as for each of the
three subcohorts. In contrast, AURKA was not signifi-
cantly associated with MFI in the ER-/HER2- and in the
Table 3 Clinicopathological characteristics of node
negative breast cancer patients (fresh frozen tissue) from









G I+II 165100 58.9
G III 15 35.7
not documented 5.4
Estrogen receptor
RNA expression low 79 28.2
RNA expression high 201 71.8
Progesterone receptor
RNA expression low 156 55.7






RNA expression low 245 87.5




Estrogen receptor, progesterone receptor and HER-2 status were derived from
the gene array data. Cutpoints were 8.2 for the estrogen receptor, 10.2 for
HER-2, and 4.5 for the progesterone receptor. Log2 transformed gene array
data have been used.
1The hormone receptor status is positive when either the estrogen or
progesterone receptor RNA expression is high.
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analysis adjusted to age, pTstage and histological grade,
AURKA was also significantly associated with MFI in
the ER+/HER2- (Table 5) but not in the ER-/HER2-
(Table 6) carcinomas. The association in the HER2+
subgroup (Table 6) should be interpreted with caution
because of the small case number.
Recently, Schmidt and co-workers have identified
metagenes that represent biological motifs - prolifera-
tion, estrogen receptor and immune system - in breast
cancer[27]. AURKA shows a strong correlation with the
proliferation metagene (Figure 3A). A weaker inverse
correlation was obtained with estrogen receptor-
associated genes (Figure 3B). No or only extremely weak
correlations were obtained with the B- and T-cell meta-
genes, respectively (Figure 3C, Figure 3D). In addition,AURKA RNA levels correlated with histological grade
(P<0.001), tumor size (P<0.001) and HER2 (P<0.001).
Considering the molecular subtypes, AURKA showed
higher mRNA levels in ER-/HER2- and HER2+ tumors,
whereas expression was lower in ER+/HER2- carcinomas
(Figure 4A). A similar pattern was observed for the pro-
liferation metagene (Figure 4B). Similarly as observed for
AURKA, also the proliferation metagene was associated
with MFI in ER+/HER2- but not in ER-/HER2- nor in
HER2+ carcinomas (Additional file 1: Table S1). In con-
clusion, the correlation of AURKA with metagenes and
clinical factors reflects the characteristic pattern of a
proliferation-associated gene.
Given the high correlation of AURKA and histological
grade and the association of grading with prognosis we
analyzed whether there is a real benefit of considering
AURKA expression. For this purpose we performed an
analysis similarly as Prat and co-workers [32]. To com-
pare the amount of independent prognostic information
provided by AURKA we estimated the likelihood ratio
statistic in a model that already included grading
(Figure 5). The model showed that AURKA provided
significant additional information over grading in the
cohort of all patients, as well as in the ER+/HER2- and
in the HER2+ subgroups. In previous publications
Ep-CAM was described as strong prognostic factor in
breast cancer [33,34]. The likelihood ratio statistic shows
that AURKA also adds independent prognostic informa-
tion over Ep-CAM in the cohort of all patients as well as
in the ER+/HER2- subgroup Additional file 2: Figure S1.
In the present study the Affymetrix probe set
204092_s_at was used as a measure of AURKA expres-
sion. However, similar results were obtained also with
the probe set 208079_s_at, which highly correlates with
204092_s_at (R=0.920; P<0.001) (Additional file 1: Figure
S1 and Additional file 1: Table S2). A third probe set
(208080_at) did not correlate with the other probe sets
and should therefore be treated with caution.Discussion
Currently, inhibitors of aurora kinases are under preclin-
ical and clinical development [6,35,36]. However, the
available data on whether high AURKA expression is
associated with worse prognosis in breast cancer remain
controversial. Nadler et al. [17] reported an association
with survival; however, another study with 112 patients
was unable to confirm this result [16]. The discrepancy
might be explained by the relatively small case numbers.
Therefore, we used a well-established cohort of 766
node-negative breast cancer patients [27] to clarify
whether AURKA is prognostic. This cohort did not re-
ceive chemotherapy, and therefore provides ideal condi-
tions to study the natural course of the disease. In our
A B
C D
Figure 1 Metastasis-free survival (MFS) in relation to AURKA expression in the individual subcohorts (Mainz, Rotterdam and Transbig)
and in the combined cohort. A. Mainz cohort (n=200), B. Rotterdam cohort (n=286), C. Transbig cohort (n=280), and D. combined cohort
(n=766).
Table 4 AURKA is associated with metastasis-free survival (MFS) in three independent cohorts of systemically
untreated node negative breast cancer (combined Mainz, Rotterdam and Transbig cohorts, n=766)
Mainz cohort (n=200) Rotterdam cohort (n=286) Transbig cohort (n=280) Combined cohorts (n=766)
A. Univariate Cox analysis
AURKA P-value <0.001 <0.001 0.005 <0.001
HR 1.927 1.952 1.520 1.669
95%-CI 1.335-2.782 1.448-2.632 1.135-2.036 1.402-1.986
B. Multivariate Cox analysis of MFS adjusted to established clinical factors (combined Mainz and Transbig cohorts, n=465)
p HR 95% CI
Age (<50 vs. ≥50 years) 0.392 1.180 0.808-1.726
pT stage (≤2cm vs. >2cm) 0.005 1.812 1.192-2.754
Histological grade (Grade 1 and 2
vs. grade 3)
0.087 1.529 0.940-2.487
ER status (negative vs. positive) 0.413 1.214 0.763-1.931
HER2 status (negative vs. positive) 0.415 1.248 0.732-2.128
AURKA (continuous variable) 0.046 1.350 1.005-1.812
HR: hazards ratio, 95%-CI: 95% confidence interval. AURKA was analyzed as a continuous variable.
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A B
Figure 2 Relationship between AURKA levels in breast carcinomas and metastasis-free survival (MFS). A. Patients were subdivided into
four percentiles with increasing AURKA expression and analyzed by Kaplan-Meier plots. Red, green, dark blue, light blue represent the 1st, 2nd, 3rd
and 4th quartiles of AURKA expression, respectively. B. Similarly, six groups of equal case numbers were analyzed. The colors red, green, dark blue,
light blue and yellow show groups of patients with increasing AURKA expression.
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ciated with survival in the whole cohort of patients [25].
The present study demonstrates that high AURKA ex-
pression is associated with worse prognosis in univariate
analysis. AURKA was not only significant in the totalTable 5 Cox analysis of metastasis-free survival (MFS) in the m
according to Desmedt and co-workers [31]
Mainz cohort (n=158) Rotterdam cohort (n=178) Tra
A. Univariate analysis
ER+/HER2-
AURKA P-value 0.011 <0
HR 1.786 2.9
95%-CI 1.144-2.787 2.0
Mainz cohort (n=23) Rotterdam cohort (n=58) Tra
ER-/HER2-
AURKA P-value 0.497 0.8
HR 1.534 1.1
95%-CI 0.446-5.282 0.4
Mainz cohort (n=19) Rotterdam cohort (n=50=) Tra
HER2+
AURKA P-value 0.298 0.8
HR 2.303 1.0
95%-CI 0.478-11.091 0.4
AURKA is associated with MFS in the estrogen receptor positive but not in the estro(combined) cohort, but also in each of the three individ-
ual subcohorts (Mainz, Rotterdam, Transbig) that were
recruited at different centers. Besides showing an associ-
ation in the univariate Cox model, AURKA was also sig-
nificant in the multivariate regression adjusted toolecular subtypes (ER+/HER; ER-/HER2-; HER2+)












gen receptor negative subtypes. A. Univarate analysis.
Table 6 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+)
according to Desmedt and co-workers [31]
p HR 95% CI
B. Multivariate analysis
ER+/HER2- (n=332)
Age (<50 vs. ≥50 years) 0.920 1.025 0.634-1.656
pT stage (≤2cm vs. >2cm) 0.004 2.143 1.271-3.613
Histological grade (Grade 1 and 2 vs. grade 3) 0.456 1.255 0.691-2.283
AURKA (continuous variable) 0.001 1.734 1.242-2.419
p HR 95% CI
ER-/HER2- (n=80)
Age (<50 vs. ≥50 years) 0.644 0.825 0.365-1.865
pT stage (≤2cm vs. >2cm) 0.466 1.459 0.528-4.028
Histological grade (Grade 1 and 2 vs. grade 3) 0.590 0.768 0.294-2.005
AURKA (continuous variable) 0.858 0.943 0.497-1.791
p HR 95% CI
HER2+ (n=53)
Age (<50 vs. ≥50 years) 0.018 5.072 1.327-19.383
pT stage (≤2cm vs. >2cm) 0.485 1.510 0.475-4.802
Histological grade (Grade 1 and 2 vs. grade 3) 0.001 15.527 3.223-74.793
AURKA (continuous variable) 0.001 0.146 0.045-0.466
AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. B. Multivariate Cox regression.
A B
C D
Figure 3 Correlation of AURKA expression with biological motifs expressed by metagenes [27]: A. Proliferation, B. Estrogen receptor,
C. B-cell and D. T-cell metagenes.
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A B
Figure 4 Beanplots showing expression levels of AURKA (A) and the proliferation metagene (B) in the three different molecular
subtypes of breast cancer in each individual subcohort (Mainz, Rotterdam and Transbig) and in the combined cohort (all). The small
lines represent the data points. The median is represented by a longer line.
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considered that AURKA performed differently in the
three molecular subtypes of breast cancer. Whereas a
significant association was obtained in the ER+/HER2-
carcinomas, no association with prognosis was seen in
the ER-/HER2- and in the HER2+ carcinomas. The
strong prognostic impact of AURKA in ER+/HER2- car-
cinomas is in agreement with the recent observation
made by Haibe-Kains and co-workers [37]. These
authors used AURKA in addition to ER and HER2 to ro-
bustly define breast cancer subtypes. Expression of
AURKA distinguished ER+/HER2- low-risk luminal A
like carcinomas from ER+/HER2- high-risk luminal B
like carcinomas. In addition to this finding, the different
result in estrogen receptor positive and negative patients
may have important clinical implications. It is tempting
to speculate that aurora kinase A inhibitors may be less
efficient in estrogen receptor negative carcinomas where
AURKA is not associated with prognosis.
Our findings concerning the different performance of
AURKA in the different molecular breast cancer sub-
types may explain the contradictory results on the prog-
nostic role of AURKA in the studies of Royce et al. [16]
and Nadler et al. [17]. Royce and co-workers did not ob-
serve an association of AURKA with survival. However,
this study included a relatively high fraction of ER-
patients (33% ER and/or PR positive, 32.1% ER and PR
negative, 34.8% unknown). In contrast, in our study 79%,
62.2% and 66.4% of the patients were ER+ in the Mainz,
Rotterdam and Transbig cohorts, respectively. The studygroup of Nadler also included a relatively high fraction
of hormone receptor positive (52% ER+ and 46% PR+)
patients. Therefore, the different numbers of hormone
receptor-positive patients in the individual groups may
explain the discrepancy.
To illustrate the biological function of AURKA, we
analyzed its correlation with metagenes of biological
motifs [27]. AURKA strongly correlated with the prolif-
eration metagene. Conversely, no relevant correlations
were obtained with the immune (B- and T-cell) meta-
genes. Therefore, AURKA seems to reflect the degree of
proliferation of carcinomas which is in agreement with
its biological function in mitosis [2,5].
It might appear controversial that AURKA is not sig-
nificantly associated with worse prognosis in ER-/HER2-
and HER2+ tumors although they express even higher
levels of AURKA and the proliferation metagene. How-
ever, previous studies have already demonstrated that
other biological motifs are relevant for the prognosis of
ER- and HER2+ carcinomas, particularly an immune cell
signature [27] which is best represented by IGKC as a
biomarker [38].
Conclusion
We have shown that AURKA is prognostic in breast
cancer patients who did not receive chemotherapy. The
prognostic impact of AURKA is most significant in the
ER+/HER2- molecular subgroup. The present study has
two potential implications for clinical studies with
AURKA inhibitors: (i) ER+ patients seem more suitable.
Figure 5 Metastasis free survival likeliehood statistics as described by Prat et al., [32]. To compare the amount of independent prognostic
information provided by grading (A) and AURKA (B) we estimated the likelihood ratio statistic in a model that already included AURKA (A) or
grading (B). The model shows that AURKA provides significant additional information over grading in the cohort of all patients, as well as in the
ER+/HER2- and in the HER2+ subgroups (B). Vice versa, grading provides additional information over AURKA only in the subcohort ofHER2+
patients (A).
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of AURKA showed a particularly poor prognosis. There-
fore, monitoring AURKA expression will be especially
beneficial for patients with high AURKA levels who may
profit from chemotherapy with AURKA inhibitors.
Additional files
Additional file 1: Table S1. Cox analysis of metastasis free survival
(MFS) in the single cohorts, in the combined cohort and in the molecular
subtypes (ER+/HER2-, ER-/HER2-, HER2+) according to Desmedt (2008).
The proliferation metagene is associated with MFI in the estrogen
receptor positive but not in the estrogen receptor negative subtypes.
Figure S1: Scatter plots showing correlation of AURKA probe sets.
Whereas 208079_s_at and 204092_s_at highly correlate with each other
the probe set 208080_at shows poor correlation with the other two.
Table S2: Similarly as the probe set described in the main manuscript
(204092_s_at) the AURKA probe set 208079_s_at is associated with
metastasis-free survival (MFS) in the three independent cohorts ofsystemically untreated node negative breast cancer (combined Mainz,
Rotterdam and Transbig cohorts, n=766). HR: hazards ratio, 95%-CI: 95%
confidence interval. AURKA was analyzed as a continuous variable. Table
S3: Cox analysis of metastasis-free survival (MFS) in the molecular
subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt (2008). The
AURKA probe set 208079_s_at is associated with MFI in the estrogen
receptor positive but not in the estrogen receptor negative subtypes, as
described for 204092_s_at in the main manuscript. A. Univariate analysis,
B. Multivariate Cox regression
Additional file 2: Figure S1. Metastasis free survival likeliehood statistics
as described by Prat et al., (2012). To compare the amount of
independent prognostic information provided by Ep-CAM (A) and AURKA
(B) we estimated the likelihood ratio statistic in a model that already
included AURKA (A) or Ep-CAM (B). The model shows that AURKA
provides significant additional information over grading in the cohort of
all patients, as well as in the ER+/HER2- subgroups (B). Vice versa,
Ep-CAM provides additional information over AURKA only in the cohort
of all patients.
Competing interests
The authors declare that they have no competing interests.
Siggelkow et al. BMC Cancer 2012, 12:562 Page 10 of 11
http://www.biomedcentral.com/1471-2407/12/562Authors’ contributions
MS, HK, JGH, MG conceived and designed the experiments. WS, MS, CC, SG,
JGH, MG performed the experiments. WS, MS, BH, JGH, CC, JR, SG, DB, CS, AL,
MJB, IS, CC, RM, analyzed the data. WS, MS, JGH, CC wrote the paper. All
authors read and approved the final manuscript.Authors’ information
Jan G Hengstler and Marcus Schmidt shared senior authorship.
Author details
1Department of Obstetrics and Gynecology, Diakonischen Dienste Hannover
GmbH, Diakoniekrankenhaus Henriettenstiftung und Diakoniekrankenhaus
Friederikenstift, Hanover, Germany. 2Department of Obstetrics and
Gynecology, Johannes Gutenberg University, Mainz, Germany. 3Department
of Statistics, Dortmund TU, Dortmund, Germany. 4Bayer GmbH, Leverkusen,
Germany. 5IfADo-Leibniz Research Centre for Working Environment and
Human Factors (IfADo), Technical University of Dortmund, Dortmund,
Germany. 6Department of Obstetrics and Gynecology, University of Mainz,
Langenbeckstr. 1, Mainz 55131, Germany.
Received: 14 May 2012 Accepted: 23 November 2012
Published: 27 November 2012References
1. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev
Canc 2004, 4:927–936.
2. Fu J, Bian M, Jiang Q, Zhang C: Roles of Aurora kinases in mitosis and
tumorigenesis. Mol Canc Res 2007, 5:1–10.
3. Carmena M, Earnshaw WC: The cellular geography of aurora kinases. Nat
Rev Mol Cell Biol 2003, 4:842–854.
4. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B,
Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ,
Plowman GD: A homologue of drosophila aurora kinase is oncogenic
and amplified in human colorectal cancers. EMBO J 1998, 17:3052–3065.
5. Marumoto T, Zhang D, Saya H: Aurora-A - a guardian of poles. Nat Rev
Canc 2005, 5:42–50.
6. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO,
Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec
JMC, Miller KM: VX-680, a potent and selective small-molecule inhibitor
of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004,
10:262–267.
7. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock
A, Keen N, Taylor SS: Aurora B couples chromosome alignment with
anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell
Biol 2003, 161:267–280.
8. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van
Meel J, Rieder CL, Peters J: The small molecule Hesperadin reveals a role
for Aurora B in correcting kinetochore-microtubule attachment and in
maintaining the spindle assembly checkpoint. J Cell Biol 2003,
161:281–294.
9. Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S, Suzuki F, Terada
Y, Tatsuka M: Mitotic kinase expression and colorectal cancer
progression. J Natl Canc Inst 1999, 91:1160–1162.
10. Cox DG, Hankinson SE, Hunter DJ: Polymorphisms of the AURKA (STK15/
aurora kinase) gene and breast cancer risk (United States). Canc Causes
Control 2006, 17:81–83.
11. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker
J, Ashworth A, Peto J: Inconsistent association between the STK15 F31I
genetic polymorphism and breast cancer risk. J Natl Canc Inst 2006,
98:1014–1018.
12. Dai Q, Cai Q, Shu X, Ewart-Toland A, Wen W, Balmain A, Gao Y, Zheng W:
Synergistic effects of STK15 gene polymorphisms and endogenous
estrogen exposure in the risk of breast cancer. Canc Epidemiol Biomarkers
Prev 2004, 13:2065–2070.
13. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP,
Deng C, Sen S, Lee SW, Ouchi T: BRCA1 phosphorylation by Aurora-A in
the regulation of G2 to M transition. J Biol Chem 2004, 279:19643–19648.
14. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y: Centrosomal
kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast.
Canc Res 1999, 59:2041–2044.15. Miyoshi Y, Iwao K, Egawa C, Noguchi S: Association of centrosomal kinase
STK15/BTAK mRNA expression with chromosomal instability in human
breast cancers. Int J Canc 2001, 92:370–373.
16. Royce ME, Xia W, Sahin AA, Katayama H, Johnston DA, Hortobagyi G, Sen S,
Hung M: STK15/Aurora-A expression in primary breast tumors is
correlated with nuclear grade but not with prognosis. Cancer 2004,
100:12–19.
17. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y: Expression
of Aurora A (but not Aurora B) is predictive of survival in breast cancer.
Clin Canc Res 2008, 14:4455–4462.
18. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B,
Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M,
Delorenzi M: Meta-analysis of gene expression profiles in breast cancer:
toward a unified understanding of breast cancer subtyping and
prognosis signatures. Breast Canc Res 2008, 10:R65.
19. Martin KJ, Patrick DR, Bissell MJ, Fournier MV: Prognostic breast cancer
signature identified from 3D culture model accurately predicts clinical
outcome across independent datasets. PLoS One 2008, 3:e2994.
20. van Veer LJ't, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL,
van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM,
Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling
predicts clinical outcome of breast cancer. Nature 2002, 415:530–536.
21. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P,
Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H,
Nuyten D, Buyse M, van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene
expression profiling in breast cancer: understanding the molecular basis
of histologic grade to improve prognosis. J Natl Canc Inst 2006,
98:262–272.
22. Teschendorff AE, Mook S, Reyal F, van Vliet MH, Armstrong NJ, Horlings HM,
de Visser KE, Kok M, Teschendorff AE, Mook S, van Veer L't, Caldas C,
Salmon RJ, van de Vijver MJ, Wessels LFA: A comprehensive analysis of
prognostic signatures reveals the high predictive capacity of the
proliferation, immune response and RNA splicing modules in breast
cancer. Breast Canc Res 2008, 10:R93.
23. Ali HR, Dawson S, Blows FM, Provenzano E, Pharoah PD, Caldas C: Aurora
kinase A outperforms Ki67 as a prognostic marker in ER-positive breast
cancer. Br J Canc 2012, 106:1798–1806.
24. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G: A comparative study of
survival models for breast cancer prognostication based on microarray
data: does a single gene beat them all? Bioinformatics 2008, 24:2200–
2208.
25. Schmidt M, Petry I, Boehm D, Gebhard S, Lebrecht A, Koelbl H, Gehrmann
M, Hengstler JG: Prognostic significance of Aurora kinase A expression in
three cohorts of node-negative breast cancer patients. Canc Res 2010,
70:33s.
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM:
REporting recommendations for tumor MARKer prognostic studies
(REMARK). Breast Canc Res Treat 2006, 100:229–235.
27. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr H,
Hengstler JG, Kölbl H, Gehrmann M: The humoral immune system has a
key prognostic impact in node-negative breast cancer. Canc Res 2008,
68:5405–5413.
28. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D,
Foekens JA: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 2005, 365:671–679.
29. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL,
Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong
time dependence of the 76-gene prognostic signature for node-
negative breast cancer patients in the TRANSBIG multicenter
independent validation series. Clin Canc Res 2007, 13:3207–3214.
30. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris
A, Bergh J, Foekens JA, Klijn JGM, Larsimont D, Buyse M, Bontempi G,
Delorenzi M, Piccart MJ, Sotiriou C: Definition of clinically distinct
molecular subtypes in estrogen receptor-positive breast carcinomas
through genomic grade. J Clin Oncol 2007, 25:1239–1246.
31. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G,
Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with
breast cancer clinical outcome depend on the molecular subtypes. Clin
Canc Res 2008, 14:5158–5165.
Siggelkow et al. BMC Cancer 2012, 12:562 Page 11 of 11
http://www.biomedcentral.com/1471-2407/12/56232. Prat A, Parker JS, Fan C, Perou CM: PAM50 assay and the three-gene
model for identifying the major and clinically relevant molecular
subtypes of breast cancer. Breast Canc Res Treat 2012, 135:301–306.
33. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E,
Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H,
Gehrmann M, Lehr H, Koelbl H, Hengstler JG, Schuler M: Prognostic effect
of epithelial cell adhesion molecule overexpression in untreated node-
negative breast cancer. Clin Canc Res 2008, 14:5849–5855.
34. Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-
Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K,
Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler
JG: Ep-CAM RNA expression predicts metastasis-free survival in three
cohorts of untreated node-negative breast cancer. Breast Canc Res Treat
2011, 125:637–646.
35. Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SJ,
Lee M: Antineoplastic effects of an Aurora B kinase inhibitor in breast
cancer. Mol Canc 2010, 9:42.
36. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander
K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D: GSK1070916, a
potent Aurora B/C kinase inhibitor with broad antitumor activity in
tissue culture cells and human tumor xenograft models. Mol Canc Ther
2009, 8:1808–1817.
37. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J,
Sotiriou C: A three-gene model to robustly identify breast cancer
molecular subtypes. J Natl Canc Inst 2012, 104:311–325.
38. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D,
Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach
C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M,
Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian
M, Kronenwett R, Bojar H, Lehr H, et al: A comprehensive analysis of
human gene expression profiles identifies stromal immunoglobulin κ C
as a compatible prognostic marker in human solid tumors. Clin Canc Res
Offic J Am Assoc Canc Res 2012, 18:2695–2703.
doi:10.1186/1471-2407-12-562
Cite this article as: Siggelkow et al.: Expression of aurora kinase A is
associated with metastasis-free survival in node-negative breast cancer
patients. BMC Cancer 2012 12:562.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
